208 related articles for article (PubMed ID: 26164541)
21. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
Elliott CS; Shinghal R; Presti JC
Clin Cancer Res; 2009 Jul; 15(14):4694-9. PubMed ID: 19584168
[TBL] [Abstract][Full Text] [Related]
22. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
[TBL] [Abstract][Full Text] [Related]
23. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
28. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
29. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
[TBL] [Abstract][Full Text] [Related]
30. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
31. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
[TBL] [Abstract][Full Text] [Related]
32. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
33. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
34. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
35. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
36. PHI in the Early Detection of Prostate Cancer.
Fuchsova R; Topolcan O; Windrichova J; Hora M; Dolejsova O; Pecen L; Kasik P; Novak J; Casova M; Smejkal J
Anticancer Res; 2015 Sep; 35(9):4855-7. PubMed ID: 26254378
[TBL] [Abstract][Full Text] [Related]
37. Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions.
Nordström T; Adolfsson J; Grönberg H; Eklund M
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27418620
[TBL] [Abstract][Full Text] [Related]
38. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
39. PSA velocity and PSA slope.
Benecchi L
Prostate Cancer Prostatic Dis; 2006; 9(2):169-72. PubMed ID: 16568147
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
